|
Participants (N = 52)
n (%)
|
Sex |
|
Female
|
27 (51.9%)
|
Male
|
25 (48.1%)
|
Race/Ethnicity |
|
Non-Hispanic white
|
25 (48.1%)
|
Non-Hispanic black
|
14 (26.9%)
|
Hispanic
|
10 (19.2%)
|
Asian
|
3 (5.8%)
|
Age at primary malignancy diagnosis, in years (mean / SD / range)
|
12.9 ± 7.1 (0 - 25)
|
0-11 years old
|
19 (36.5%)
|
12-17 years old
|
15 (28.9%)
|
≥18 years old
|
18 (34.6%)
|
Age at assessment, in years (mean / SD / range)
|
13.8 ± 7.2 (0 - 25)
|
0-11 years old
|
18 (34.6%)
|
12-17 years old
|
14 (26.9%)
|
≥18 years old
|
20 (38.5%)
|
Primary malignancy diagnosis |
|
Leukemia
|
30 (57.7%)
|
CNS tumor
|
3 (5.8%)
|
Hodgkin lymphoma
|
6 (11.5%)
|
Non-Hodgkin lymphoma
|
2 (3.9%)
|
Neuroblastoma
|
4 (7.7%)
|
Wilms tumor
|
2 (3.9%)
|
Soft tissue sarcoma
|
1 (1.9%)
|
Bone tumor
|
2 (3.9%)
|
Other*
|
2 (3.9%)
|
Treatment type |
|
Surgery
|
16 (30.8%)
|
Radiation
|
7 (13.5%)
|
Chemotherapy
|
51 (91.8%)
|
Stem cell transplantation
|
4 (7.7%)
|
Other
|
3 (5.8%)
|
Health insurance |
|
Private
|
36 (69.2%)
|
Medicaid
|
14 (26.9%)
|
Other
|
2 (3.9%)
|
Annual household income |
|
Less than $20,000
|
11 (21.2%)
|
$20,000 to $49,999
|
5 (9.6%)
|
$50,000 to $99,999
|
12 (23.1%)
|
$100,000 to $149,999
|
7 (13.5%)
|
$150,000 to $199,999
|
4 (7.7%)
|
$200,000 or more
|
5 (9.6%)
|
Don’t know/Unsure
|
8 (15.4%)
|
Any chronic health condition
|
27 (51.9%)
|
Vision/Eye problems
|
16 (30.8%)
|
Hearing problems
|
0 (0%)
|
Speech problems
|
3 (5.8%)
|
Any endocrine
|
1 (1.9%)
|
Any cardiac/vascular
|
3 (5.8%)
|
Any respiratory
|
3 (5.8%)
|
Any GI/digestive
|
1 (1.9%)
|
Any renal
|
2 (3.8%)
|
Any brain/nervous system
|
3 (5.8%)
|
Any musculoskeletal
|
0 (0%)
|
Chronic pain
|
1 (1.9%)
|
Any psychiatric/mental health diagnosis
|
18 (34.6%)
|
Substance misuse
|
|
Tobacco use**
|
8 (15.4%)
|
Risky alcohol use***
|
12 (23%)
|
Recreational/Prescription drug use****
|
10 (19.2%)
|